SCHEMBL3030650

SCHEMBL3030650

O=Cc1ccc(-c2ccc(F)cc2F)o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
KDM4E B2RXH2 3/20 0.59
LMNA P02545 2/20 0.59
PIK3CG P48736 3/20 0.56
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
ATM Q13315 1/20 0.51
SLC9A1 P19634 1/20 0.48
PDE4B Q07343 3/20 0.46
POLB P06746 3/20 0.46
MAPT P10636 3/20 0.46
PDE4D Q08499 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
TP53 P04637 2/20 0.43
PIK3CA P42336 2/20 0.42
PIK3CD O00329 1/20 0.42
CSNK2A2 P19784 1/20 0.42
PIK3CB P42338 1/20 0.42
CSNK2B P67870 1/20 0.42
CSNK2A1 P68400 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21823823 0.83 ALDH1A1 (0.47) ALDH1A1KDM4ELMNAPIK3CGMEN1
SCHEMBL3043067 0.83 ALDH1A1 (0.47) ALDH1A1KDM4ELMNAPIK3CGMEN1
SCHEMBL3037013 0.83 KDM4E (0.56) ALDH1A1KDM4ELMNAPIK3CGMEN1
SCHEMBL27330464 0.80 ALDH1A1 (0.56) ALDH1A1KDM4ELMNAPIK3CGMEN1
SCHEMBL6009918 0.80 ALDH1A1 (0.56) ALDH1A1KDM4ELMNAPIK3CGMEN1
SCHEMBL3042946 0.80 KDM4E (0.51) ALDH1A1KDM4ELMNAPIK3CGMEN1
SCHEMBL3043232 0.79 KDM4E (0.58) ALDH1A1KDM4ELMNAPIK3CGMEN1
SCHEMBL31358724 0.76 PIK3CG (0.56) ALDH1A1KDM4EPIK3CGMEN1KMT2A
SCHEMBL2325829 0.74 KDM4E (1.00) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL6010187 0.73 SLC9A1 (0.50) ALDH1A1KDM4ELMNAPIK3CGMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3860994-B1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE UNIV BRITISH COLUMBIA (CA) 2024-08-14 EP disclosed
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2022-04-07 US disclosed
EP-3860994-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE The University of British Columbia (CA) 2021-08-11 EP disclosed
WO-2020069625-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2020-04-09 WO disclosed
US-8338465-B2 Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis CORNELL RESEARCH FOUNDATION, INC. (US) 2012-12-25 US disclosed
US-20100210577-A1 CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS CORNELL RESEARCH FOUNDATION, INC. 2010-08-19 US disclosed
US-7432263-B2 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them PFIZER ITALIA, S.R.L. (IT) 2008-10-07 US disclosed
EP-1427708-B1 AMINO-PHTHALAZINONE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER ITALIA SRL (IT) 2008-09-10 EP disclosed
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed
US-20050020583-A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them PFIZER ITALIA S.R.L. (IT) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 ALDH1A1 4446/4885KDM4E 1799/4885LMNA 2808/4885
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use BRDT, CBFB, CREBBP ALDH1A1 3522/4885KDM4E 2015/4885LMNA 227/4885
US-20050020583-A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them MAP3K20, MAP3K1, MAP3K15 ALDH1A1 3566/4885KDM4E 710/4885LMNA 2414/4885
US-20100210577-A1 CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS RARG, SDHA, RARS2 ALDH1A1 270/4885KDM4E 4138/4885LMNA 3523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.